3 citations
,
October 2025 in “Cancer” PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
November 2001 in “Oncology Times” The committee decided not to approve the drug due to low effectiveness and high risks.
10 citations
,
October 2011 in “Dermatologica Sinica” A patient with PPP had rare skin reactions to adalimumab, which improved after stopping smoking and continuing acitretin.
32 citations
,
May 2016 in “European journal of dermatology/EJD. European journal of dermatology” Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.
14 citations
,
August 2019 in “Dermatologic Therapy”
4 citations
,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
20 citations
,
November 2017 in “JAAD case reports” Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.
1 citations
,
May 2023 in “Prospects in Pharmaceutical Sciences” New cytokine-targeted therapies show promise for treating alopecia areata.
June 2025 in “Acta Dermato Venereologica” Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.
April 2026 in “Journal of Inflammation Research” Alopecia areata and atopic dermatitis share immune system issues, and treatments like JAK inhibitors can help both.
May 2026 in “Frontiers in Immunology” Bimekizumab effectively treats scalp cellulitis and improves quality of life.
23 citations
,
November 2015 in “Phytotherapy Research” Certain herbal compounds, especially from bitter melon, can inhibit cancer growth and promote hair growth by blocking PAK1.
July 2025 in “Journal of Investigative Dermatology”
August 2025 in “JEADV Clinical Practice” PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.
January 2026 in “Journal of Clinical Medicine” Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
6 citations
,
May 2024 in “JAAD Case Reports” Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
290 citations
,
August 2021 in “Clinical Reviews in Allergy & Immunology” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
38 citations
,
January 2009 in “Journal of Cutaneous Medicine and Surgery” A woman developed hair loss after starting a treatment with adalimumab, suggesting this medication might cause hair loss.
68 citations
,
November 2015 in “The Journal of Allergy and Clinical Immunology” Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.
55 citations
,
October 2015 in “Journal of Investigative Dermatology” Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.
June 2024 in “Dermatology and Therapy” Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
4 citations
,
January 2001 in “Archives of Biochemistry and Biophysics” Activated ras can protect kidney cells from a certain substance that causes cell death.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
147 citations
,
October 2021 in “Cancer Communications” RC48 shows promise for treating certain advanced cancers, but more research is needed.
July 2025 in “Clinical Medicine” Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
October 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib may help young adults with severe alopecia areata when ketoconazole fails.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Targeting specific metabolic and ionic pathways may improve alopecia areata treatment.
11 citations
,
December 2013 in “Clinical and Experimental Dermatology” Sorafenib often causes skin side effects, indicating effective cancer treatment.